ERBB2 and neoplasm: Further, addition of lapatinib or the HER2 antibody trastuzumab to XL-147 in mice with established BT474 xenografts resulted in better growth inhibition as well as reduction of tumor levels of P-HER3, P-AKT, and P-S6.